GEN Exclusives

More »

GEN News Highlights

More »
Feb 9, 2009

AstraZeneca Licenses Antidepressant Compounds Discovered in Mayo Clinic and Virginia Tech Collaboration

  • AstraZeneca has licensed a portfolio of preclinical triple reuptake inhibitor (TRI) compounds for depression that were discovered by researchers from Virginia Tech and Mayo Clinic. The agreement provides AstraZeneca with a global license for all uses of the compounds, as well as exclusive manufacturing and commercial rights. It also establishes a research collaboration that will focus on jointly generating additional novel TRI compounds.

    "Together with our colleagues at Mayo Clinic, we have been seeking wider-spectrum behavior and have developed a portfolio of TRIs to address imbalances associated with the three major neurotransmitters,” explains Paul R. Carlier, professor of organic and medicinal chemistry at Virginia Tech. “Besides incorporating all the benefits associated with serotonin and norepinephrine inhibition, our TRI compounds include the additional action of the dopamine neurotransmitter. We are excited to discover additional compounds that work through this unique mechanism."



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?